Skin & Cosmetic Peptides: The Complete Reference

Skin peptides are short amino-acid chains studied for dermal effects — collagen synthesis, elastin preservation, dynamic-wrinkle reduction, melanogenesis, and wound repair. Two sub-classes are routinely conflated by consumers. The first is the cosmetic-peptide class: Matrixyl, Argireline, the palmitoyl tripeptides, SNAP-8, SYN-AKE, Heptapeptide-7, Leuphasyl, and Epitide. These compounds are topically applied, sold in commercial skincare at regulated concentrations, carry cosmetic-grade safety data from multiple Phase 2/3 topical trials, and are explicitly permitted under the EU Cosmetic Regulation and the US Federal Food, Drug, and Cosmetic Act. The second is the research-peptide class: Alpha-MSH, Melanotan-II, PTD-DBM, GHK-Cu at research doses, Palmitoyl Oligopeptide, Palmitoyl Hexapeptide-12, and the oral-collagen peptides (Collagen Type I, Collagen Type III, Collagen Dipeptide, Collagen Peptides). These are investigational or off-label — including systemic administration routes that are not FDA-approved for any cosmetic indication. The cosmetic-peptide subclass has the strongest evidence base of any peptide category PeptaHub covers, with decades of formulation experience and a well-characterized safety profile, but effect sizes are modest: 15–35% wrinkle-depth reduction over 8–12 weeks is typical, versus 60%+ with Botox or 80%+ with a retinoid-plus-sunscreen regimen. Systemic injection of a skin peptide — most notoriously melanotan-II for tanning or PTD-DBM for hair loss — moves entirely into research-chemical risk territory. The hub below covers 17 compounds total, ordered by evidence tier and delivery route, with direct links to each profile's mechanism, dosing, and safety section.

Skin peptides work through five mechanisms that map cleanly to cosmetic claims. (1) Neurotransmitter blockade — Argireline, SNAP-8, and SYN-AKE block acetylcholine release at the neuromuscular junction, reducing dynamic wrinkles via a topical-Botox-analog pathway (with a far smaller effect than injected botulinum toxin). (2) Matrix signaling — Matrixyl and the palmitoyl tripeptides signal fibroblasts to upregulate collagen and glycosaminoglycan synthesis by mimicking matrikines, endogenous peptide fragments that coordinate wound remodeling. (3) Copper delivery and antioxidant defense — GHK and GHK-Cu drive collagen synthesis, quench reactive oxygen species, and promote glycosaminoglycan expression. (4) Melanogenesis and pigmentation — Alpha-MSH and Melanotan-II activate MC1R on melanocytes to stimulate eumelanin production. (5) Specialized pathways — Leuphasyl is an enkephalin analog that modulates neurotransmitter release, and PTD-DBM inhibits the CXXC5-Dishevelled interaction in hair-follicle Wnt signaling. Oral collagen peptides work differently: Pro-Hyp and Hyp-Gly dipeptides survive gut digestion, enter plasma, and signal fibroblast collagen synthesis in the dermis indirectly.

Neurotransmitter-blocking peptides (Argireline, SNAP-8, SYN-AKE)

Argireline (acetyl hexapeptide-8) is a truncated mimic of the N-terminus of SNAP-25, the SNARE-complex protein that botulinum toxin type A cleaves. By competitively binding SNARE-complex components, Argireline inhibits acetylcholine vesicle fusion at the neuromuscular junction, reducing the force of facial-muscle contraction that produces dynamic wrinkles. SNAP-8 (acetyl octapeptide-3) is a two-amino-acid extension of Argireline that Lipotec markets on the basis of improved skin penetration and a claimed 30%+ wrinkle reduction versus Argireline's 10–20%. SYN-AKE (dipeptide diaminobutyroyl benzylamide diacetate) takes a different route to the same outcome: it is a synthetic mimic of Waglerin-1, a toxin from the Temple Viper Tropidolaemus wagleri, which acts as a nicotinic-acetylcholine-receptor antagonist at the post-synaptic membrane. All three are cosmetic-approved topical actives; all three produce 5–30% dynamic-wrinkle reduction in placebo-controlled trials; none approaches the efficacy of injected neuromodulators.

Matrix-signaling peptides (Matrixyl and the palmitoyl tripeptide family)

Matrixyl (palmitoyl pentapeptide-4, sequence Pal-KTTKS) is the archetype of this class. The pentapeptide KTTKS is a fragment of type-I procollagen that signals dermal fibroblasts to ramp up collagen I, collagen III, and glycosaminoglycan synthesis; the palmitic acid tail conjugated to the N-terminus drives lipid-bilayer penetration through the stratum corneum, solving the delivery problem that kept earlier peptide cosmetics from working. The palmitoyl tripeptide family — Palmitoyl Tripeptide-1 (Pal-GHK, an extension of the GHK-Cu mechanism), Palmitoyl Tripeptide-5 (the SYN-COLL active), and Palmitoyl Tripeptide-38 (Epitide, the Matrixyl synthe'6 active) — expands on the same matrikine concept with different target gene sets. Palmitoyl Oligopeptide, Palmitoyl Tetrapeptide-7, and Palmitoyl Hexapeptide-12 round out the Sederma/Lipotec/DSM product lines. All are cosmetic-approved.

Copper-tripeptide chemistry (GHK, GHK-Cu)

GHK (glycyl-L-histidyl-L-lysine) is a naturally-occurring tripeptide released from collagen during tissue damage. In the presence of Cu(II), it forms the GHK-Cu complex with a characteristic 1:1 copper-to-peptide stoichiometry. The complex regulates collagen and glycosaminoglycan synthesis, quenches reactive oxygen species, modulates matrix metalloproteinases, and — per Pickart's 2018 review — induces more than 4,000 gene-expression changes in fibroblasts. GHK-Cu is cosmetic-approved for topical wrinkle and repair applications and is cross-listed in the Recovery pillar for its wound-healing evidence base. The copper-free form (GHK) is included in some formulations for users with copper sensitivity, though the metal coordination is central to the complete mechanism.

Melanogenesis and hair-follicle signaling (Alpha-MSH, Melanotan-II, PTD-DBM, oral collagen peptides)

Alpha-MSH (the 13-amino-acid α-melanocyte-stimulating hormone) is the endogenous MC1R agonist that drives eumelanin biosynthesis in melanocytes. Melanotan-II is a cyclic lactam analog of alpha-MSH with nonselective activity across MC1R through MC5R receptors — which is why it tans (MC1R), suppresses appetite (MC4R), and produces penile erection (MC3/MC4R), an adverse-event profile that makes it particularly unsuitable as a tanning agent. PTD-DBM is a cell-penetrating peptide that inhibits the CXXC5-Dishevelled interaction, derepressing Wnt signaling in hair follicles and driving regeneration in preclinical models. Oral collagen peptides (gelatin hydrolysates and their Pro-Hyp / Hyp-Gly active dipeptides) reach the dermis via plasma and signal fibroblasts indirectly — the mechanism is less direct than topical actives but has the strongest human RCT base in the category, with approximately 15 placebo-controlled trials showing modest hydration and fine-line improvements at 2.5–10 g/day over 8–12 weeks.

17 peptides, ordered by clinical evidence tier. Each entry links to the full profile with mechanism, dosing, side effects, and legal-status detail.

Skin is the only PeptaHub pillar where cosmetic FDA approval covers most of the hub. But cosmetic approval is not pharmaceutical approval — it regulates topical use in marketed products at specified concentrations, not injection or systemic administration. The comparison table orders compounds by regulatory status first (cosmetic-approved, then research) and secondarily by mechanism group.

Matrixyl is the most-formulated skin peptide globally. Argireline has the most name recognition in the consumer market. GHK-Cu has the broadest evidence base across wrinkles, wound healing, and hair — and is the only compound on this hub cross-listed in the Recovery pillar. Oral collagen peptides have the strongest human RCT base of any peptide on the hub, with approximately 15 placebo-controlled trials showing modest dermal improvements. Melanotan-II is the category outlier — a research peptide frequently purchased from gray-market suppliers for tanning, with documented serious adverse events including priapism, melanoma, and darkening of moles. The rational approach to topical cosmetic peptides is to treat them as modest-effect adjuncts to a retinoid-plus-SPF core regimen, not standalone anti-aging treatments.

Skin peptide safety separates cleanly into three layers. (1) Cosmetic-topical peptides carry the strongest safety record of any peptide class covered on PeptaHub — decades of formulation experience, CIR (Cosmetic Ingredient Review) assessments, compliance with the EU Cosmetic Regulation (EC) No 1223/2009, and adverse events limited to mild erythema and rare sensitization. (2) Oral collagen peptides are GRAS-classified foods with no appreciable safety concern at typical 10 g/day doses. (3) Research-peptide systemic use — melanotan-II injection, alpha-MSH, PTD-DBM — carries the full research-chemical risk profile: no pharmaceutical sterility or potency controls, unquantified long-term effects, and for melanotan-II specifically documented serious adverse events including melanoma, priapism, new or darkening moles, and ischemic events (UK MHRA, FDA, and NHS have issued multiple warnings). PeptaHub's legal-status methodology is documented at /methodology.

Skin peptides are simultaneously the most evidence-solid peptide category PeptaHub covers at the cosmetic tier and the most-abused category at the research tier. Users looking for topical anti-aging support can reasonably consider Matrixyl, Argireline, GHK-Cu, and palmitoyl-tripeptide formulations as adjuncts — but should calibrate expectations to 5–35% improvement over 8–12 weeks, not dramatic transformation. Users considering injected melanotan-II for tanning should understand they are self-administering a research chemical with documented serious adverse events for an entirely cosmetic indication; the risk/benefit is unfavorable even by biohacker standards. The rational approach is topical cosmetic peptides at labeled concentrations alongside a retinoid-plus-broad-spectrum-SPF core regimen — anything beyond that is either investigational or actively risky.

How this class connects to the rest of PeptaHub's peptide coverage. Start with the full category index if you want to browse everything.

External citations underpinning this page. PeptaHub's full sourcing methodology is documented at /methodology — every claim on this page traces back to one of these references or a linked profile.

• Argireline and wrinkle clinical research (PubMed search) — PubMed
• GHK-Cu wound healing literature (PubMed search, 48 results) — PubMed
• Matrixyl / palmitoyl pentapeptide research (PubMed search) — PubMed
• EU Cosmetic Regulation (EC) No 1223/2009 — EUR-Lex
• FDA Cosmetics Laws & Regulations — FDA

See also: glossary, FAQ, about PeptaHub.